All In Biotech

Drug Trial Radar · NCT06906198

Pharmacokinetics of VVN461 Ophthalmic Solution

A Randomized, Double-Masked, Vehicle-Controlled, Single-Center Phase 1 Clinical Study Evaluating the Safety, Tolerability and Pharmacokinetics of 0.25%, 0.5% and 1.0% VVN461 Ophthalmic Solution

Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 1, 2023

Primary completion

May 10, 2023

Study completion Dec 22, 2023

Sponsor

Lead sponsor
VivaVision Biotech, IncIndustry
Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, double-masked, randomized, vehicle-controlled study conducted in China in adult healthy subjects

Conditions

  • Healthy Volunteers

Interventions

  • VVN461 Ophthalmic Solution 1.0%Drug

    VVN461, 1.0%

  • VVN461 Ophthalmic Solution 0.5%Drug

    VVN461, 0.5%

  • VVN461 Ophthalmic Solution 0.25%Drug

    VVN461, 0.25%

  • VVN461 Ophthalmic Solution PlaceboDrug

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety outcomeTime frame: Baseline to Day 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.